Emerging role of inositol monophosphatase in cancer - 28/03/23
Abstract |
Inositol monophosphatase (IMPase) is an enzyme with two homologs—IMPA1 and IMPA2—that is responsible for dephosphorylating myo-inositol monophosphate to generate myo-inositol. IMPase has been extensively studied in neuropsychiatric diseases and is regarded as a susceptibility gene. Recently, emerging evidence has implied that IMPase is linked to cancer development and progression and correlates with patient survival outcomes. Interestingly, whether it acts as a tumor-promoter or tumor-suppressor is inconsistent among different research studies. In this review, we summarize the latest findings on IMPase in cancer, focusing on exploring the underlying mechanisms for its pro- and anticancer roles. In addition, we discuss the potential methods of IMPase regulation in cancer cells and the possible approaches for IMPase intervention in clinical practice.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The role of IMPase in cancer has not been revealed until recently. |
• | IMPase can act as both a tumor-promoter and tumor-inhibitor. |
• | IMPase is associated with a number of crucial biological processes in cancer cells. |
• | Cancer cell can modify IMPase at the levels of gene expression and enzyme-activity. |
• | Intervening IMPase with chemical compounds is a potential cancer treatment strategy. |
Abbreviations : AMP, BLBC, ccRCC, DLBCL, EMT, GEPIA, IMPase, IMPA1, IMPA2, IP2, IP3, ISYNA1, miRNA, mRNA, PI, PIP, PIP2, PIP3, SNP, TCGA, UTR
Keywords : IMPase, IMPA1, IMPA2, Myo-inositol, Cancer
Plan
Vol 161
Article 114442- mai 2023 Retour au numéro
Article précédent
- The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
- Sajad Najafi, Jamal Majidpoor, Keywan Mortezaee
- A mechanistic updated overview on lycopene as potential anticancer agent
- Gulay Ozkan, Deniz Günal-Köroğlu, Ayse Karadag, Esra Capanoglu, Susana M. Cardoso, Basem Al-Omari, Daniela Calina, Javad Sharifi-Rad, William C. Cho
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?